CFTR and cystic fibrosis: We previously published pioneering data that underscored a substantial change in the impact of Aspergillus-related diseases in patients with cystic fibrosis (pwCF) treated with a combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, so-called Trikafta (1).